In episode 27 of We’re doomed, We’re saved , the bio revolution podcast Andreas Horchler and Louise von Stechow talk about the potential of Artificial Intelligence (AI) in drug discovery and development. The pharma industry is struggling with high development costs and failure rates. Can AI help to overcome those challenges, and what is hype and what is reality?
In episode 26 of We’re doomed we’re saved we talk about the future trends in medicine, such as technologization, virtualization, predictive orientation and patient centration. These trends are corroborated by new technologies, such as artificial intelligence (AI), telemedicine, wearable devices and smart sensors.
Listen to We're doomed, We're saved, the bio revolution podcast with Andreas Horchler and Louise von Stechow here.
In episode 25 of We’re doomed we’re saved we talk to idalab founder and mathematician, Paul von Bünau we discuss the promise and challenges of Large Language Models (LLMs) in the biomedical field and ask the question if we can ever stop them from hallucinating.
Rare or orphan diseases affect only a small percentage of the population and often lack effective treatments. While rare individually, in total, more than 350 million people worldwide live with rare diseases. Many of these are very hard to diagnose, let alone cure, and the rarity of patients challenges the development of novel treatments.
To make the development of drugs for rare diseases more efficient and successful, artificial intelligence (AI) could be an important ally not only for drug makers but also for patients.
A revolution driven by novel biotechnologies (gene editing, neuroprosthetics, synthetic biology, and artificial intelligence in biotech) has the potential to not only change the way we live but the very foundations of our lives – our biology.
But is the so-called biorevolution a real "scientific revolution"?
In the new episode of "We're Doomed, We're Saved," Andreas Horchler and Louise von Stechow look at the biorevolution from different angles, examining its transformative potential and comparing it to revolutions that came before.
In episode 27 of We’re doomed, We’re saved , the bio revolution podcast Andreas Horchler and Louise von Stechow talk about the potential of Artificial Intelligence (AI) in drug discovery and development. The pharma industry is struggling with high development costs and failure rates. Can AI help to overcome those challenges, and what is hype and what is reality?
In episode 26 of We’re doomed we’re saved we talk about the future trends in medicine, such as technologization, virtualization, predictive orientation and patient centration. These trends are corroborated by new technologies, such as artificial intelligence (AI), telemedicine, wearable devices and smart sensors.
Listen to We're doomed, We're saved, the bio revolution podcast with Andreas Horchler and Louise von Stechow here.
Rare or orphan diseases affect only a small percentage of the population and often lack effective treatments. While rare individually, in total, more than 350 million people worldwide live with rare diseases. Many of these are very hard to diagnose, let alone cure, and the rarity of patients challenges the development of novel treatments.
To make the development of drugs for rare diseases more efficient and successful, artificial intelligence (AI) could be an important ally not only for drug makers but also for patients.
A revolution driven by novel biotechnologies (gene editing, neuroprosthetics, synthetic biology, and artificial intelligence in biotech) has the potential to not only change the way we live but the very foundations of our lives – our biology.
But is the so-called biorevolution a real "scientific revolution"?
In the new episode of "We're Doomed, We're Saved," Andreas Horchler and Louise von Stechow look at the biorevolution from different angles, examining its transformative potential and comparing it to revolutions that came before.
